Overview

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

Status:
Terminated
Trial end date:
2017-10-16
Target enrollment:
Participant gender:
Summary
Systemic safety following single and multiple dermal administration of BAY1003803
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Clobetasol